ABSTRACT
Costeff syndrome is a rare genetic neuro-ophthalmological syndrome consisting of early-onset bilateral optic atrophy along with a progressive complex motor disorder with elevated levels of urinary 3-methylglutaconic acid and 3-methylglutaric acid. While borderline to mild cognitive deficits have been considered to be common in patients with this syndrome, a comprehensive cognitive assessment has never been performed. The aim of the current study was to explore the cognitive profile associated with Costeff syndrome. Sixteen adult patients diagnosed with Costeff syndrome were administered a neuropsychological test battery that was composed of standardized verbal tests adapted for the blind. General intelligence ranged from average to borderline, with a group mean consistent with intact general cognitive functioning (VIQmean = 85, z = -1) in the low-average range of the general population. The auditory immediate and delayed memory indexes were in the average range and were significantly higher than the general cognitive functioning, whereas the working memory index was significantly lower than the general cognitive functioning. Adult patients with Costeff syndrome have intact global cognition and learning abilities and strong auditory memory performance. © 2015 Wiley Periodicals, Inc.
Subject(s)
Chorea/complications , Chorea/psychology , Cognition Disorders/etiology , Cognition Disorders/psychology , Meglutol/analogs & derivatives , Metabolism, Inborn Errors/complications , Metabolism, Inborn Errors/psychology , Optic Atrophy/complications , Optic Atrophy/psychology , Spastic Paraplegia, Hereditary/complications , Spastic Paraplegia, Hereditary/psychology , Adult , Executive Function/physiology , Female , Follow-Up Studies , Humans , Intelligence/physiology , Male , Meglutol/urine , Memory, Short-Term/physiology , Middle Aged , Neuropsychological Tests , Prognosis , Psychomotor Performance , Young AdultABSTRACT
Background: Cerebrotendinous xanthomatosis (CTX) is a rare lipid storage disease, caused by deficiency of sterol-27-hydroxylase. Xanthomatous lesions in numerous tissues, and an elevation of cholestanol levels, characterize the disease. Its natural course is progressive neurologic deterioration, leading to premature death. Chronic treatment with oral chenodeoxycholic acid (CDCA) reduces cholestanol levels. Occurrence of premature atherosclerosis has been described in CTX in an unknown mechanism. Aim: The aim of the current work was to evaluate the potential metabolic abnormalities and preclinical vascular changes in Israeli CTX patients. Methods: Ten subjects with CTX were studied. Features of the metabolic syndrome were evaluated, and carotid intima media thickness (cIMT) was measured in the common carotid arteries. Results: All patients were diagnosed with CTX, and all received treatment with CDCA, which resulted in normalization of their plasma cholestanol levels. At the conclusion of the follow up, risk factors for CVD and features of MS were present in all the patients and in three patients, cIMT was higher compared to control subjects. Conclusion: Cardiovascular risk factors and premature vascular changes exist in young CTX patients and proper assessment should be implemented with preventive measures to reduce the risk of atherosclerotic cardiovascular disease in CTX patients.
ABSTRACT
The risk of melanoma is higher in patients with Parkinson's disease (PD) than in the general population. Whether the association is disease related or treatment related is unclear. The objective of this study was to assess melanoma prevalence in PD patients in Israel using active dermatologic screening. Consecutive patients with idiopathic PD were recruited by 12 Israeli centers. A movement disorder specialist assessed the severity of PD and obtained a medical, neurological, and medication history. Subsequently, a dermatologist assessed melanoma risk factors, recorded a dermatologic history, proactively performed a whole-body skin examination, and biopsied suspicious skin lesions. Of the enrolled patients (n = 1,395, mean age 69.5 ± 10.6 years, mean PD duration 7.3 ± 6.0 years), 95.3% were treated with dopaminergic agents. Biopsies revealed 8 patients with melanoma in situ and 1 with invasive malignant melanoma; 14 patients reported a melanoma prior to enrollment. The observed 5-year limited duration prevalence of melanoma in PD patients was 4.4 times greater (95% CI 2.6-7.6) than expected from melanoma prevalence in an age- and sex-matched cohort from the Israel National Cancer Registry. The increase was accounted for by an elevated prevalence of melanoma in situ [relative risk 12.5 (95% CI 6.7-23.2)]. Occurrence of melanoma did not correlate with levodopa therapy or time of onset of PD. Melanoma prevalence in PD patients was higher than expected in the general Israeli population. This was not related to levodopa treatment. PD patients should be actively screened for melanoma on a routine basis.
Subject(s)
Melanoma/epidemiology , Parkinson Disease/epidemiology , Skin Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Antiparkinson Agents/therapeutic use , Cohort Studies , Female , Humans , Israel/epidemiology , Male , Melanoma/diagnosis , Middle Aged , Parkinson Disease/diagnosis , Parkinson Disease/drug therapy , Prevalence , Skin Neoplasms/diagnosisABSTRACT
OBJECTIVES: To determine the relationship between apolipoprotein E (APOE) polymorphisms to the time to appearance of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. METHODS: The APOE genotype of 155 consecutive patients treated with levodopa was determined and its effect on the time of onset of LID was examined using Cox regression model, controlling for gender, age of disease onset, time to initiation of levodopa treatment and history of smoking. RESULTS: Two patients were homozygous for the APOE ε2 allele, 7 had ε2/ε3, 1 had ε2/ε4, 130 had ε3/ε3, 12 had ε3/ε4 and 3 had ε4/ε4; LID appeared in 57.4% of the patients, appearing 4.1 ± 3.5 years after the initiation of levodopa treatment. The survival curve for LID was not affected by the APOE genotype (P = 0.34). CONCLUSION: APOE polymorphisms were found not to be associated with either the occurrence or the time to development of LID.
Subject(s)
Antiparkinson Agents/adverse effects , Apolipoproteins E/genetics , Dyskinesia, Drug-Induced/etiology , Dyskinesia, Drug-Induced/genetics , Levodopa/adverse effects , Polymorphism, Genetic/genetics , Aged , Aged, 80 and over , Dyskinesia, Drug-Induced/mortality , Female , Gene Frequency , Genotype , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Parkinson Disease/drug therapy , Parkinson Disease/genetics , Retrospective StudiesABSTRACT
Myofascial pain of the muscles of mastication is a common temporomandibular disorder. Patients unresponsive to conservative treatment modalities pose a therapeutic challenge to the treating clinician. The efficacy of intramuscular botulinum toxin injections for recalcitrant cases is still not well established due to mixed results from clinical trials. The Diagnostic Criteria of Temporomandibular Disorders (DC/TMD) classified chronic muscle pain broadly into a localized pattern (when pain is localized to the site of palpation or the muscle palpated) and a referring pattern (when the pain spreads beyond the boundary of the muscle being palpated). The medical records of 25 consecutive patients treated with botulinum were analysed retrospectively. Significant pain reduction was achieved in 69.2% of the patients with localized myofascial pain and 16.7% of the patients with referring myofascial pain (P=0.015). Seventy-seven per cent of the patients with localized myofascial pain reported using less analgesic throughout the follow-up period, whereas only 25% of the patients with referring myofascial pain (P=0.017). The effects of botulinum toxin in responsive patients subsided after a mean of 3.21 months. Patients with localized myofascial pain benefited from botulinum toxin injections, but patients with referring myofascial pain responded poorly to this treatment.
Subject(s)
Botulinum Toxins, Type A/administration & dosage , Myofascial Pain Syndromes/drug therapy , Neuromuscular Agents/administration & dosage , Pain, Referred/drug therapy , Temporomandibular Joint Disorders/drug therapy , Adult , Aged , Female , Humans , Injections, Intramuscular , Male , Middle Aged , Pain Measurement , Retrospective Studies , Treatment OutcomeABSTRACT
A retrospective analysis of consecutive Parkinson's disease (PD) patients hospitalized in internal medicine wards during the years 2008 to 2013 due to infectious disease was performed. PD patients are prone to infections, often leading to hospitalization in internal medicine wards. We observed that during these hospitalizations, chronic anti-Parkinson's medications are frequently overlooked and withdrawn, their reintroduction is delayed and dosages are decreased. Only patients on chronic therapy with at least one anti-Parkinson's medication were included in this study. Multivariate analyses established the association between medication dose reductions on short-term clinical outcomes, including in-hospital mortality and change in discharge destination. Medical records from 528 PD patients were analyzed and 430 were excluded. Of the 98 included, 53 had pneumonia and 58 had urinary tract infections. The overall in-hospital mortality rate was 11.2%. 56.1% of patients' dopaminergic medications were decreased in dose upon admission (22.5% mean decrease in levodopa equivalent daily dose [LEDD]; p<0.001). Both absolute and relative LEDD reductions were associated with significantly increased in-hospital mortality (mean reduction of 394.5 mg versus 188.4 mg; p=0.035 by analysis of variance adjusted to age, sex and renal function) and was also associated with worse discharge destination relative to original place of arrival (mean reduction of 377.8 mg versus 150.7 mg; p=0.014). Decreased dopaminergic medication dosing upon admission of PD patients due to infection is widespread and potentially associated with worse clinical outcomes.
Subject(s)
Antiparkinson Agents/therapeutic use , Dopamine Agents/therapeutic use , Infections/complications , Parkinson Disease/complications , Parkinson Disease/drug therapy , Aged , Aged, 80 and over , Cohort Studies , Female , Hospital Mortality , Humans , Infections/mortality , Male , Middle Aged , Pneumonia/complications , Pneumonia/drug therapy , Pneumonia/mortality , Prognosis , Retrospective Studies , Socioeconomic Factors , Treatment Outcome , Urinary Tract Infections/complications , Urinary Tract Infections/drug therapy , Urinary Tract Infections/mortalityABSTRACT
INTRODUCTION: Parkinson's disease (PD) displays an individually variable rate of progression, of which the underlying mechanisms are largely unknown, but may involve genetic factors. In this study, we aimed to explore the effect of ethnic origin on PD progression rate in Israeli Jews, as expressed by time from onset until reaching Hoehn and Yahr stage 3 (HY3). METHODS: Consecutive patients with PD followed bi-annually at the Movement Disorders Institute at Sheba Medical Center, were included. Demographic data and clinical information, including age at PD onset (AO), H&Y staging, and family history of PD, were collected. Ethnicity was determined based on the parents' origin and was categorized as Ashkenazi Jews (AJ), Yemenite Jews (YJ), North African Jews (NAJ) and Oriental Jews (OJ) excluding YJ. Associations between the above variables and the time to HY3 were determined using Cox proportional hazards model. Survival curves were derived from the model. RESULTS: Of 707 patients [430 males, AJ: 458, YJ: 37, NAJ: 75 and OJ: 137] included in the analysis, 343 had reached HY3. In a multivariate analysis, a longer time to HY3 was significantly associated with a younger AO (HR = 1.07, p < 0.001). YJ showed a significantly shorter time to HY3 compared to AJ and OJ, but not compared to NAJ. Time to HY3 was significantly shorter for NAJ than for OJ. CONCLUSION: Jewish PD patients of Yemenite and North African origin may have a more rapid progression of PD, compared to those of Ashkenazi and Oriental origin, suggesting distinctive genetic influences.
Subject(s)
Disease Progression , Parkinson Disease/ethnology , Parkinson Disease/epidemiology , Africa, Northern , Age Factors , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Judaism , Male , Middle Aged , Sex Factors , Survival Analysis , YemenABSTRACT
Down's syndrome (DS) patients who survive beyond the third decade develop brain lesions characteristic of Alzheimer's disease (AD). Sera of AD patients contain antibodies that bind specifically to the heavy neurofilament protein (NF-H) of Torpedo cholinergic neurons. In the present report, we examined whether the AD-like pathologic changes in DS are associated with the existence of such antibodies. Our findings show that IgG of older DS patients (greater than 30 years) binds to Torpedo cholinergic NF-H more readily than does that of young DS patients (less than 30 years) and age-matched normal controls. In contrast, the extent of binding of IgG from the young and older DS groups to Torpedo and bovine spinal cords NF-H is similar and equal to that of normal controls. These findings suggest that older DS patients, like AD patients, contain anti-NF-H IgG that binds specifically to epitopes highly enriched in Torpedo cholinergic NF-H.
Subject(s)
Alzheimer Disease/immunology , Antibodies/immunology , Choline O-Acetyltransferase/immunology , Down Syndrome/immunology , Neurofilament Proteins/immunology , Adult , Animals , Female , Humans , Immunoglobulin G/analysis , Male , Middle Aged , TorpedoABSTRACT
We conducted a double-blind, placebo-controlled study of 40 patients (aged 19 to 60 years) with clinical definite relapsing remitting (RR) MS and brain MRI confirmed. Patients were randomly assigned to receive a loading dose of immunoglobulin IgG (0.4 g/kg/body weight per day for 5 consecutive days), followed by single booster doses (0.4 g/kg/body weight) or placebo once every 2 months for 2 years. The primary outcome measures were change in the yearly exacerbation rate (YER), proportion of exacerbation-free patients, and time until first exacerbation. Neurologic disability, exacerbation severity, and changes in brain MRI lesion score were the secondary outcome measures, all determined at baseline, 1 year, and on completion. Treated patients showed a reduction in YER from 1.85 to 0.75 after 1 year and 0.42 after 2 years versus 1.55 to 1.8 after 1 year and to 1.4 after 2 years in the placebo group (p = 0.0006, overall), reflecting a 38.6% reduction in relapse rate. Six patients in the IVIg group were exacerbation free throughout the 2-year period of the study, whereas none were exacerbation free in the placebo group. The median time to first exacerbation was 233 days in the IVIg group versus 82 days in the placebo group (p = 0.003). Neurologic disability as measured by the Expanded Disability Status Scale (EDSS score) decreased by 0.3 in the IVIg group and increased by 0.15 in the placebo group. Total lesion score evaluated by brain MRI did not show a significant difference between groups. Side effects were minor and occurred in only 19 of 630 (3.0%) infusions administered in both groups. Our results suggest that IVIg may be safe and effective in reducing the frequency of exacerbations in RR-MS.
Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Multiple Sclerosis/therapy , Adult , Brain/pathology , Disability Evaluation , Disease-Free Survival , Double-Blind Method , Humans , Magnetic Resonance Imaging , Middle Aged , Multiple Sclerosis/diagnosis , Multiple Sclerosis/physiopathology , Placebos , Probability , Recurrence , Survival Analysis , Time FactorsABSTRACT
Nigrostriatal dopaminergic function and cerebral energy metabolism were measured with PET in two brothers with early-onset parkinsonism caused by mutation of the parkin gene. Energy metabolism did not differ, but the nigrostriatal dopaminergic pattern was clearly different than that of sporadic PD. Thus parkinsonism in these two patients was shown to be pathophysiologically different than PD.
Subject(s)
Corpus Striatum/diagnostic imaging , Ligases/genetics , Mutation/genetics , Parkinsonian Disorders/genetics , Substantia Nigra/diagnostic imaging , Ubiquitin-Protein Ligases , Age of Onset , Brain/diagnostic imaging , Humans , Male , Middle Aged , Parkinsonian Disorders/diagnostic imaging , Tomography, Emission-ComputedABSTRACT
Ataxia-telangiectasia (AT) is an autosomal recessive multisystem disorder presenting in childhood with progressive cerebellar ataxia, oculocutaneous telangiectasia, immune deficiency, radiosensitivity, and cancer predisposition. The gene for AT, designated ATM (AT, mutated) encodes a protein with a carboxy-terminal phosphoinositide-3 kinase domain which is involved in cell cycle checkpoints and other responses to genotoxic stress. Most of the patients with the classical AT phenotype are homozygous or compound heterozygous for severe mutations causing truncation or destabilization of the ATM protein. Patients with a milder forms of disease, called AT variants, have been found to be either homozygous for milder mutations or compound heterozygotes for null alleles and mild mutations. In order to define the clinical phenotype of patients homozygous (or compound heterozygotes) for other, milder mutations, we decided to search for ATM mutations in patients with either sporadic or familial idiopathic ataxia. Thirty-four patients with idiopathic cerebellar ataxia, aged 3-77 years, were screened for mutations in the ATM coding region. There were 12 familial cases. None of the patients had abnormal immunoglobulin or alpha-fetoprotein levels, and none had mutations in the ATM coding region. In this heterogeneous group of patients with cerebellar ataxia we found no mutations in the ATM gene. We conclude that mutations in the ATM gene are probably not a common cause for cerebellar ataxia other than AT.
Subject(s)
Ataxia Telangiectasia/genetics , Cerebellar Ataxia/genetics , Genes, Recessive , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Genotype , Humans , Male , Middle Aged , Mutation , Phenotype , SyndromeABSTRACT
The syndrome of inflammatory subacute lumbosacral polyradiculoneuropathy (SLP) has been reported in acquired immunodeficiency syndrome (AIDS) patients in association with cytomegalovirus infection and is only partially amenable to anti-viral therapy. We report three cases of relatively benign inflammatory painful SLP in two non-AIDS, immunosuppressed patients and one who HIV-seroconversed at the time of clinical presentation. SLP developed: (1) in association with HIV seroconversion; (2) during ECHO virus infection in a patient with common variable immune deficiency; and (3) after a severe systemic infection that induced transient immunosuppression due to Epstein-Barr virus reactivation. This report expands the spectrum of viruses associated with acute and subacute lumbosacral polyradiculoneuropathy and may shed light on its possible pathogenesis.
Subject(s)
Agammaglobulinemia/complications , Back Pain/etiology , Epstein-Barr Virus Infections/complications , HIV Seropositivity/complications , Peripheral Nervous System Diseases/pathology , Adult , Back Pain/therapy , Diabetes Mellitus, Type 1/complications , Humans , Male , Peripheral Nervous System Diseases/etiologyABSTRACT
A 25-year-old man was admitted following deterioration in behavior and onset of blindness. He soon became comatose and died 6 weeks later. Brain biopsy showed nuclear inclusion bodies resembling viral capsids, astrocytosis and perivascular lymphocytic cuffing but no demyelination. The diagnosis of subacute sclerosing panencephalitis was made on finding: measles virus antigens in both serum and cerebrospinal fluid, the identification of measles RNA sequences in brain tissue by the polymerase chain reaction, and intense, oligoclonal, IgG-banding in the CSF. However, the relatively advanced age of the patient, the absence of myoclonus and the nondistinctive EEG profile lacking synchronous bursts of high-voltage slow and sharp waves, are unusual.
Subject(s)
Subacute Sclerosing Panencephalitis , Adult , Antigens, Viral/analysis , Brain/immunology , Brain/pathology , Fatal Outcome , Humans , Male , Measles virus/immunology , Subacute Sclerosing Panencephalitis/diagnosisABSTRACT
OBJECTIVE: In view of the fact that cancer patterns in patients with Parkinson disease (PD) differ from the general population, we aimed to verify whether patients with PD with LRRK2 mutations have an increased risk for particular cancer types. METHODS: In this cross-sectional study, eligible consenting Jewish patients with PD were genotyped for the predominant LRRK2 G2019S mutation. Oncologic data were obtained by personal interview and reviewing patients' files. Stepwise logistic regression was applied to model the probability of cancer occurrence in carriers vs noncarriers. RESULTS: Overall, 79/490 (16.1%) genotyped patients carried the G2019S mutation. Seventy-seven (16%) were diagnosed with cancer; of those, 67 (14%) with a non-skin cancer. Eighteen (23%) carriers vs 49 (12%) noncarriers had a non-skin cancer (p = 0.01, odds ratio [OR] = 2.18, 95% confidence interval [CI] 1.19-3.99). A significant ethnicity effect was noted (p = 0.045, OR = 1.84, 95% CI 1.02-3.34). Among Ashkenazi patients, age and LRRK2 emerged as significant using stepwise logistic regression including age, gender, and LRRK2 status as explanatory variables. The OR for LRRK2 mutation carriers adjusted for age was 3.38 (95% CI 1.64-6.97, p = 0.0009). CONCLUSIONS: Ashkenazi Jewish patients with PD who harbor the G2019S LRRK2 mutation are more likely to have a concomitant non-skin cancer than noncarriers.
Subject(s)
Neoplasms/complications , Neoplasms/genetics , Parkinson Disease/complications , Parkinson Disease/genetics , Protein Serine-Threonine Kinases/genetics , Age of Onset , Aged , Antiparkinson Agents/therapeutic use , Cross-Sectional Studies , Ethnicity , Female , Genetic Predisposition to Disease , Heterozygote , Humans , Jews , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Levodopa/therapeutic use , Logistic Models , Male , Middle Aged , Mutation/physiology , Neoplasms/epidemiology , Parkinson Disease/epidemiology , Sex Factors , Survival AnalysisABSTRACT
Yemenite Jews in Israel are a distinctive ethnic division of the Jewish diaspora. Clinical findings, disease course and genetic tests for the LRRK2 6055G > A (G2019S) mutation were compared between Ashkenazi and Yemenite Israeli patients with Parkinson's disease (PD). Age of onset was significantly younger in the Yemenites (P < 0.001). There were no differences in the distribution of initial symptoms, environmental risk factors or rate of motor/non-motor phenomena. The Yemenite group had a more severe disease (P < 0.001), and a more rapid disease course (P = 0.006). The frequency of Lrrk2 substitution was 12.7% in the Ashkenazi group and was not observed in the Yemenites. These results show that there are differences between Israeli Jewish ethnic groups in the severity and progression of PD, but not in clinical symptoms. The high frequency of Lrrk2 G2019S in the Ashkenazi and its absence in the Yemenite Jews suggests a specific ancestral pattern of inheritance in Ashkenazi Jews.
Subject(s)
Genetic Predisposition to Disease/ethnology , Jews/ethnology , Parkinson Disease/ethnology , Parkinson Disease/physiopathology , Protein Serine-Threonine Kinases/genetics , Age of Onset , Aged , DNA Mutational Analysis , Disease Progression , Environment , Female , Gene Frequency/genetics , Genetic Predisposition to Disease/genetics , Genetic Testing , Genotype , Humans , Inheritance Patterns/genetics , Israel/epidemiology , Jews/genetics , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Male , Middle Aged , Mutation/genetics , Parkinson Disease/genetics , Severity of Illness Index , Yemen/ethnologyABSTRACT
OBJECTIVES: To study the frequency of different gene mutations in patients with early-onset parkinsonism and bilateral subthalamic nucleus deep brain stimulation (STN-DBS) and the short- and long-term surgical outcome in mutation-positive (MUT+) and -negative (MUT-) patients. METHODS: Eighty patients with disease onset at age Subject(s)
Electric Stimulation Therapy/statistics & numerical data
, Parkinson Disease/genetics
, Parkinson Disease/therapy
, Protein Kinases/genetics
, Subthalamic Nucleus/surgery
, Ubiquitin-Protein Ligases/genetics
, Adult
, Aged
, DNA Mutational Analysis
, Electric Stimulation Therapy/methods
, Female
, Follow-Up Studies
, Functional Laterality/genetics
, Gene Frequency
, Genetic Predisposition to Disease/genetics
, Genetic Testing
, Genotype
, Heterozygote
, Humans
, Male
, Middle Aged
, Mutation/genetics
, Parkinson Disease/physiopathology
, Prospective Studies
, Recovery of Function/genetics
, Subthalamic Nucleus/physiopathology
, Treatment Outcome
ABSTRACT
Neurologic disorders are among the most prominent clinical manifestations associated with the antiphospholipid syndrome. Such neurologic disorders are predominantly related to focal central nervous system thrombo-occlusive events. This review summarizes the latest data regarding the clinical aspects of stroke and other neurologic manifestations associated with antiphospholipid antibodies.
Subject(s)
Antibodies, Antiphospholipid/analysis , Antiphospholipid Syndrome/diagnosis , Central Nervous System Diseases/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Alzheimer Disease/etiology , Antiphospholipid Syndrome/complications , Brain Ischemia/diagnosis , Brain Ischemia/etiology , Brain Ischemia/immunology , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/immunology , Cerebrovascular Disorders/diagnosis , Cerebrovascular Disorders/etiology , Cerebrovascular Disorders/immunology , Child , Chorea/diagnosis , Chorea/etiology , Chorea/immunology , Dementia/diagnosis , Dementia/etiology , Dementia/immunology , Female , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/etiology , Guillain-Barre Syndrome/immunology , Humans , Intracranial Thrombosis/diagnosis , Intracranial Thrombosis/etiology , Intracranial Thrombosis/immunology , Ischemic Attack, Transient/diagnosis , Ischemic Attack, Transient/etiology , Ischemic Attack, Transient/immunology , Male , Middle Aged , Migraine Disorders/diagnosis , Migraine Disorders/etiology , Migraine Disorders/immunology , Multiple Sclerosis/diagnosis , Multiple Sclerosis/etiology , Multiple Sclerosis/immunology , Risk FactorsABSTRACT
Kurtzke's EDSS remains the most widely-used measure for clinical evaluation of MS patients. However, several studies have demonstrated the limited reliability of this tool. We introduce a computerized instrument, MS-CANE (Multiple Sclerosis Computer-Aided Neurological Examination), for clinical evaluation and follow up of patients with multiple sclerosis (MS) and to compare its reliability to that of conventional Expanded Disability Status Scale (EDSS) assessment. We developed a computerized interactive instrument, based on the following principles: structured gathering of neurological findings, reduction of compound notions to their basic components, use of precise definitions, priority setting and automated calculations of EDSS and functional systems scores. An expert panel examined the consistency of MS-CANE with Kurtzke's specifications. To determine the effect of MS-CANE on the reliability of EDSS assessment, 56 MS patients underwent paired conventional EDSS and MS-CANE-based evaluations. The inter-observer agreement in both methods was determined and compared using the kappa statistic. The expert panel judged the tool to be compatible with the basic concepts of Kurtzke's EDSS. The use of MS-CANE increased the reliability of EDSS assessment: Kappa statistic was found to be 0.42 (i.e. moderate agreement) for conventional EDSS assessment versus 0.69 (i.e. substantial agreement) for MS-CANE (P=0.002). We conclude that the use of this tool may contribute towards a standardized and reliable assessment of EDSS. Within clinical trials, this could increase the power to detect effects, thus reducing trial duration and the cohort size required. Multiple Sclerosis (2000) 6 355 - 361
Subject(s)
Diagnosis, Computer-Assisted/methods , Disability Evaluation , Multiple Sclerosis/diagnosis , Multiple Sclerosis/rehabilitation , Algorithms , Diagnosis, Computer-Assisted/standards , Humans , Neurologic Examination , Reproducibility of Results , Software DesignABSTRACT
In order to characterize the clinical spectrum of neuroleptic-induced parkinsonism (NIP), we studied a population of consecutive psychiatric in-patients treated with neuroleptics for at least two weeks, who were diagnosed by their psychiatrist as having parkinsonism. Parkinsonism was confirmed by a movement disorders specialist who performed neurological assessment including the motor examination and the activities of daily living (ADL) sections of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Hoehn and Yahr (H&Y) staging. Seventy-five patients (54 males), aged 46 +/- 13 years (range 21 to 73 years) were included in the analysis. The mean duration of neuroleptic therapy was 15 +/- 12 years, while 61% were treated for more than 10 years. Most of the patients (n = 66, 88%) were scored as H&Y stage 2.5 or less. Rest tremor was present in 44% of the patients, and usually persisted in action. Forty-one patients (61%) had symmetrical involvement. Parkinsonian signs were significantly more common and pronounced in the upper in comparison with the lower limbs (p = 0.0001). Gait disturbances were mild and freezing of gait was very rare (n = 2). Neither age nor duration of therapy or their interaction affected the total motor score or any of the motor sub-scores. In conclusion, NIP differs from PD for more bilateral involvement with relative symmetry, and by affecting upper limbs more often than the lower ones. NIP tends to be associated with the triad of bradykinesia, tremor and rigidity while PD tends to involve gait and posture more often. NIP develops unrelated to duration of neuroleptic treatment or age of the patient, suggesting an individual predisposition to blockage of the dopaminergic receptors.
Subject(s)
Antipsychotic Agents/adverse effects , Parkinson Disease, Secondary/chemically induced , Activities of Daily Living/psychology , Adult , Age Factors , Aged , Antipsychotic Agents/therapeutic use , Female , Functional Laterality/drug effects , Gait Disorders, Neurologic/chemically induced , Gait Disorders, Neurologic/physiopathology , Gait Disorders, Neurologic/psychology , Humans , Male , Mental Disorders/drug therapy , Mental Disorders/physiopathology , Mental Disorders/psychology , Middle Aged , Muscle Rigidity/chemically induced , Muscle Rigidity/physiopathology , Muscle Rigidity/psychology , Neurologic Examination , Parkinson Disease/physiopathology , Parkinson Disease/psychology , Parkinson Disease, Secondary/physiopathology , Parkinson Disease, Secondary/psychology , Tremor/chemically induced , Tremor/physiopathology , Tremor/psychologyABSTRACT
The authors performed linkage analysis in 39 families with autosomal recessive early-onset PD (AR-EOPD) negative for parkin and DJ-1 mutations. Eight families including three Japanese, two Taiwanese, one Turkish, one Israeli, and one Philippine showed evidence of linkage with PARK6 with multipoint log of the odds (lod) score of 9.88 at D1S2732. The results indicate worldwide distribution of PARK6-linked parkinsonism.